<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Infographic: Clinical Trial Insurance Opportunity in Indonesia</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
            -webkit-font-smoothing: antialiased;
            -moz-osx-font-smoothing: grayscale;
        }
        .icon-bg {
            background-color: #E0F2F1; /* A light teal */
        }
        .icon-color {
            color: #00796B; /* A darker teal */
        }
        .highlight-color {
            color: #FFC107; /* Amber */
        }
        .line-connector {
            width: 2px;
            background-color: #BDBDBD; /* Gray */
            height: 40px;
        }
    </style>
</head>
<body class="bg-gray-50">

    <div class="max-w-4xl mx-auto p-4 md:p-8 bg-white shadow-2xl my-8 rounded-lg">
        
        <!-- Header -->
        <header class="text-center mb-10 border-b pb-6">
            <h1 class="text-3xl md:text-4xl font-extrabold text-gray-800">The Opportunity for Clinical Trial Insurance in Indonesia</h1>
            <p class="mt-3 text-lg text-gray-600">A Strategic Overview for Establishing a Compliant and Competitive Product</p>
            <p class="mt-4 text-sm text-gray-500">Based on analysis by dr. Ahmad Hidayat, MSc, MBA</p>
        </header>

        <main class="space-y-12">

            <!-- Section 1: The Evolving Risk Landscape -->
            <section>
                <h2 class="text-2xl font-bold text-center text-teal-800 mb-6">1. The Evolving Risk Landscape of Clinical Trials</h2>
                <div class="grid grid-cols-1 md:grid-cols-4 gap-6 text-center">
                    <!-- Phase I -->
                    <div class="bg-gray-100 p-4 rounded-lg shadow-md">
                        <div class="w-16 h-16 icon-bg rounded-full mx-auto flex items-center justify-center mb-3">
                            <svg class="w-8 h-8 icon-color" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M16 7a4 4 0 11-8 0 4 4 0 018 0zM12 14a7 7 0 00-7 7h14a7 7 0 00-7-7z"></path></svg>
                        </div>
                        <h3 class="font-bold text-lg text-gray-800">Phase I</h3>
                        <p class="text-sm text-gray-600 font-semibold">First-in-Human</p>
                        <p class="mt-2 text-xs text-gray-500"><strong>Key Risk:</strong> Unpredictable toxicity & severe adverse events in small cohorts.</p>
                    </div>
                    <!-- Phase II -->
                    <div class="bg-gray-100 p-4 rounded-lg shadow-md">
                        <div class="w-16 h-16 icon-bg rounded-full mx-auto flex items-center justify-center mb-3">
                            <svg class="w-8 h-8 icon-color" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M17 20h5v-2a3 3 0 00-5.356-1.857M17 20H7m10 0v-2c0-.656-.126-1.283-.356-1.857M7 20H2v-2a3 3 0 015.356-1.857M7 20v-2c0-.656.126-1.283.356-1.857m0 0a5.002 5.002 0 019.288 0M15 7a3 3 0 11-6 0 3 3 0 016 0zm6 3a2 2 0 11-4 0 2 2 0 014 0zM7 10a2 2 0 11-4 0 2 2 0 014 0z"></path></svg>
                        </div>
                        <h3 class="font-bold text-lg text-gray-800">Phase II</h3>
                        <p class="text-sm text-gray-600 font-semibold">Efficacy & Safety</p>
                        <p class="mt-2 text-xs text-gray-500"><strong>Key Risk:</strong> High efficacy failure rate & adverse events in patient populations.</p>
                    </div>
                    <!-- Phase III -->
                    <div class="bg-gray-100 p-4 rounded-lg shadow-md">
                        <div class="w-16 h-16 icon-bg rounded-full mx-auto flex items-center justify-center mb-3">
                           <svg class="w-8 h-8 icon-color" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M17 21v-2a4 4 0 00-4-4H5a4 4 0 00-4 4v2"></path><circle cx="9" cy="7" r="4"></circle><path d="M23 21v-2a4 4 0 00-3-3.87"></path><path d="M16 3.13a4 4 0 010 7.75"></path></svg>
                        </div>
                        <h3 class="font-bold text-lg text-gray-800">Phase III</h3>
                        <p class="text-sm text-gray-600 font-semibold">Large-Scale Confirmation</p>
                        <p class="mt-2 text-xs text-gray-500"><strong>Key Risk:</strong> Rare/long-term AEs emerge, significant operational & multi-center risks.</p>
                    </div>
                    <!-- Phase IV -->
                    <div class="bg-gray-100 p-4 rounded-lg shadow-md">
                         <div class="w-16 h-16 icon-bg rounded-full mx-auto flex items-center justify-center mb-3">
                            <svg class="w-8 h-8 icon-color" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M3.055 11H5a2 2 0 012 2v1a2 2 0 002 2h10a2 2 0 002-2v-1a2 2 0 012-2h1.945M7.905 11A9 9 0 0112 3c4.97 0 9 4.03 9 9v7a2 2 0 01-2 2h-1.26a1 1 0 01-.95-.684l-1.08-3.166a1 1 0 00-.95-.684H8.26a1 1 0 00-.95.684L6.23 18.316a1 1 0 01-.95.684H4a2 2 0 01-2-2v-7c0-1.578.413-3.069 1.14-4.395M12 6a3 3 0 100-6 3 3 0 000 6z"></path></svg>
                        </div>
                        <h3 class="font-bold text-lg text-gray-800">Phase IV</h3>
                        <p class="text-sm text-gray-600 font-semibold">Post-Marketing</p>
                        <p class="mt-2 text-xs text-gray-500"><strong>Key Risk:</strong> Long-tail liability from rare AEs identified in real-world populations.</p>
                    </div>
                </div>
            </section>
            
            <!-- Section 2: The Regulatory Trinity -->
            <section>
                <h2 class="text-2xl font-bold text-center text-teal-800 mb-8">2. Navigating Indonesia's Regulatory Trinity</h2>
                <div class="grid grid-cols-1 md:grid-cols-3 gap-8">
                    <!-- BPOM -->
                    <div class="text-center p-4">
                        <img src="https://placehold.co/100x100/1E88E5/FFFFFF?text=BPOM" alt="BPOM Icon" class="mx-auto mb-4 rounded-full">
                        <h3 class="text-xl font-bold text-blue-800">BPOM</h3>
                        <p class="font-semibold text-blue-700 mb-2">The Mandate</p>
                        <p class="text-gray-600"><strong>Reg. 8/2024</strong> mandates that sponsors provide compensation (can be via insurance) for trial-related injuries, making this a compliance necessity.</p>
                    </div>
                    <!-- OJK -->
                    <div class="text-center p-4">
                        <img src="https://placehold.co/100x100/43A047/FFFFFF?text=OJK" alt="OJK Icon" class="mx-auto mb-4 rounded-full">
                        <h3 class="text-xl font-bold text-green-800">OJK</h3>
                        <p class="font-semibold text-green-700 mb-2">The Product & Financial Governance</p>
                        <p class="text-gray-600">Approves all insurance products (<strong>POJK 8/2024</strong>), governs policy wording, and enforces solvency & capital requirements for insurers.</p>
                    </div>
                    <!-- Kemenkes -->
                    <div class="text-center p-4">
                        <img src="https://placehold.co/100x100/F4511E/FFFFFF?text=KEMENKES" alt="Kemenkes Icon" class="mx-auto mb-4 rounded-full">
                        <h3 class="text-xl font-bold text-orange-800">Kemenkes</h3>
                        <p class="font-semibold text-orange-700 mb-2">The Ethical & Healthcare Oversight</p>
                        <p class="text-gray-600">Governs Ethics Committees (<strong>KEPK</strong>), who verify insurance provisions in the Informed Consent Form and define the national standard of care.</p>
                    </div>
                </div>
            </section>
            
            <!-- Section 3: The Path to an Insured Trial -->
            <section>
                <h2 class="text-2xl font-bold text-center text-teal-800 mb-8">3. The Path to an Insured Clinical Trial</h2>
                <div class="flex flex-col items-center">
                    <!-- Step 1 -->
                    <div class="flex items-center w-full max-w-md">
                        <div class="flex-shrink-0 bg-teal-600 text-white w-12 h-12 rounded-full flex items-center justify-center font-bold text-xl">1</div>
                        <div class="ml-4 p-4 bg-gray-100 rounded-lg shadow-sm w-full">
                            <h4 class="font-bold text-gray-800">Sponsor & Insurer</h4>
                            <p class="text-sm text-gray-600">Sponsor obtains a quote and "Insurance Statement" from an insurer with an <strong class="text-green-700">OJK-compliant</strong> product.</p>
                        </div>
                    </div>
                    <div class="line-connector"></div>
                    <!-- Step 2 -->
                    <div class="flex items-center w-full max-w-md">
                        <div class="flex-shrink-0 bg-teal-600 text-white w-12 h-12 rounded-full flex items-center justify-center font-bold text-xl">2</div>
                        <div class="ml-4 p-4 bg-gray-100 rounded-lg shadow-sm w-full">
                            <h4 class="font-bold text-gray-800">Ethics Committee (KEPK) Review</h4>
                            <p class="text-sm text-gray-600">Sponsor submits protocol, ICF, and proof of insurance to the <strong class="text-orange-700">KEPK</strong> for ethical approval.</p>
                        </div>
                    </div>
                    <div class="line-connector"></div>
                    <!-- Step 3 -->
                    <div class="flex items-center w-full max-w-md">
                         <div class="flex-shrink-0 bg-teal-600 text-white w-12 h-12 rounded-full flex items-center justify-center font-bold text-xl">3</div>
                        <div class="ml-4 p-4 bg-gray-100 rounded-lg shadow-sm w-full">
                            <h4 class="font-bold text-gray-800">BPOM Application</h4>
                            <p class="text-sm text-gray-600">With ethical approval, sponsor applies to <strong class="text-blue-700">BPOM</strong> for Clinical Trial Conduct Approval (PPUK).</p>
                        </div>
                    </div>
                     <div class="line-connector"></div>
                    <!-- Step 4 -->
                    <div class="flex items-center w-full max-w-md">
                        <div class="flex-shrink-0 bg-teal-600 text-white w-12 h-12 rounded-full flex items-center justify-center font-bold text-xl">
                            <svg class="w-6 h-6" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M14.752 11.168l-3.197-2.132A1 1 0 0010 9.87v4.263a1 1 0 001.555.832l3.197-2.132a1 1 0 000-1.664z"></path><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M21 12a9 9 0 11-18 0 9 9 0 0118 0z"></path></svg>
                        </div>
                        <div class="ml-4 p-4 bg-green-100 border border-green-300 rounded-lg shadow-sm w-full">
                            <h4 class="font-bold text-green-900">Trial Commencement</h4>
                            <p class="text-sm text-green-800">Upon receiving PPUK, the insured trial can officially begin.</p>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Section 4: The Strategic Solution: Tiered Insurance -->
            <section>
                <h2 class="text-2xl font-bold text-center text-teal-800 mb-6">4. The Strategic Solution: Phase-Aligned Tiered Insurance</h2>
                <div class="relative p-6 bg-gradient-to-br from-teal-50 to-blue-50 rounded-lg">
                    <div class="grid grid-cols-2 md:grid-cols-4 gap-4">
                        <div class="flex flex-col items-center p-3 text-center border-r border-gray-200">
                            <p class="font-bold text-blue-600">Tier 1</p>
                            <p class="text-sm font-semibold text-gray-700 mt-1">Phase I Focus</p>
                            <p class="text-xs text-gray-500 mt-1">Essential coverage for first-in-human risk.</p>
                        </div>
                         <div class="flex flex-col items-center p-3 text-center md:border-r border-gray-200">
                            <p class="font-bold text-teal-600">Tier 2</p>
                            <p class="text-sm font-semibold text-gray-700 mt-1">Phase II Shield</p>
                            <p class="text-xs text-gray-500 mt-1">Covers emerging AEs in patient groups.</p>
                        </div>
                         <div class="flex flex-col items-center p-3 text-center border-r border-gray-200">
                            <p class="font-bold text-indigo-600">Tier 3</p>
                            <p class="text-sm font-semibold text-gray-700 mt-1">Phase III Comprehensive</p>
                            <p class="text-xs text-gray-500 mt-1">High-limit, multi-center & global coverage.</p>
                        </div>
                         <div class="flex flex-col items-center p-3 text-center">
                            <p class="font-bold text-purple-600">Tier 4</p>
                            <p class="text-sm font-semibold text-gray-700 mt-1">Phase IV Sentinel</p>
                            <p class="text-xs text-gray-500 mt-1">Addresses long-tail liability and real-world risk.</p>
                        </div>
                    </div>
                </div>
            </section>

        </main>
        
        <!-- Footer -->
        <footer class="text-center mt-12 pt-6 border-t">
            <p class="text-lg font-semibold text-teal-800">A tiered insurance product that aligns with Indonesia's risk and regulatory landscape is key to enabling safe medical innovation.</p>
        </footer>

    </div>

</body>
</html>
